Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a caucasian population

Clinical Cancer Research

Volumn 16, Issue 21, 2010, Pages 5244-5251

  Sun, Tong ^a   Lee, Gwo Shu Mary ^a   Oh, William K ^a   Pomerantz, Mark ^a   Yang, Ming ^a   Xie, Wanling ^a   Freedman, Matthew L ^a   Kantoff, Philip W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; HERPES VIRUS ASSOCIATED UBIQUITIN SPECIFIC PROTEASE; PROLINE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CAUCASIAN; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CARCINOMA; COHORT STUDIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE;

EID: 78049472089     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1261     Document Type: Article

References (36)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
2. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
3. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-47.
4. Burchardt M, Burchardt T, Shabsigh A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate 2001;48:225-30. (Pubitemid 32816547)
5. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
6. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002;21:4037-48. (Pubitemid 34857436)
7. Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 2005;104:962-7.
8. Leite KR, Franco MF, Srougi M, et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 2001;14:428-36.
9. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007;39:1476-82. (Pubitemid 47031042)
10. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 2009;7:1-11.
11. Brooks CL, Li M, Hu M, Shi Y, Gu W. The p53-2-HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 2007;26:7262-6.
12. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
13. Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009;13:440-53.
14. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009;9:95-107.
15. Hu W, Feng Z, Atwal GS, Levine AJ. p53: a new player in reproduction. Cell Cycle 2008;7:848-52.
16. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007;26:1317-23.
17. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
18. Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 2010;120:211-6.
19. Bai J, Dai J, Yu H, Shen H, Chen F. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J Toxicol Environ Health A 2009;72:677-82.
20. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:983-6.
21. Kang HJ, Feng Z, Sun Y, et al. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A 2009;106:9761-6.
22. Atwal GS, Kirchhoff T, Bond EE, et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A 2009;106:10236-41.
23. Huang SP, Huang CY, Wang JS, et al. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007;13:6632-8.
24. Quiñones LA, Irarrázabal CE, Rojas CR, et al. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J Androl 2006;8:349-55.
25. Suzuki K, Matsui H, Ohtake N, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003;10:430-5.
26. Huang SP, Wu WJ, Chang WS, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:2217-24.
27. Stoehr R, Hitzenbichler F, Kneitz B, et al. Mdm2-309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br J Cancer 2008;99:78-82.
28. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001;49:263-6.
29. Kibel AS, Jin CH, Klim A, et al. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008;68:1179-86.
30. Hirata H, Hinoda Y, Kikuno N, et al. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009;181:1907-12.
31. Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006;5:61-6.
32. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006;2:e190.
33. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284:1280-3.
34. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-10.
35. Hu W, Feng Z, Ma L, et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007;67:2757-65.
36. Kulkarni D, Vazquez A, Haffty BG, et al. A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis 2009;30:1910-5.